We believe that this case provides valuable insights, suggesting that HCQ may offer transient symptomatic benefits, while highlighting the importance of long-term follow-up and a comprehensive evaluation of NKX2-1-associated ILD. This evidence concerns the gene NKX2-1 and interstitial lung disease.